Search results
Results From The WOW.Com Content Network
July 25, 2024 at 11:48 AM. Shares of AstraZeneca (NASDAQ: AZN) were sliding 3.2% lower as of 10:57 a.m. ET on Thursday. The decline came after the British drugmaker announced its second-quarter ...
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall ...
On Thursday, AstraZeneca Plc (NASDAQ:AZN) reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 billion. The company ...
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [11]
AstraZeneca's ( AZN) stock is up following its latest earnings report Thursday after the company reported $12.7 billion in revenue, beating consensus estimates of $11.8 billion in the first ...
July 25, 2024 at 6:22 AM. Anglo-Swedish drugmaker AstraZeneca raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic ...
AstraZeneca has set a target to become an $80 billion company, in sales, by 2030. In 2023, the company booked $45.8 billion in revenue. CFO Aradhana Sarin said she is now focused on the execution ...